Vitamin D3 for Perimenopause: Bone, Mood, and Immune Support

Vitamin D3 (cholecalciferol) is converted in the liver to 25-hydroxyvitamin D (the form measured in blood tests) and then in the kidneys to 1,25-dihydroxyvitamin D (calcitriol), the active hormone. Vitamin D receptors are found in virtually every tissue in the body, which explains the breadth of effects documented in perimenopausal women. For bone: the primary mechanism is intestinal calcium absorption. Without adequate vitamin D, only 10–15% of dietary calcium is absorbed; with vitamin D sufficiency, this rises to 30–40%. During perimenopause, estrogen withdrawal reduces osteoblast activity and increases bone resorption — and without calcium and vitamin D, there is no substrate for what little bone formation continues. Calcitriol also directly suppresses parathyroid hormone (PTH), which otherwise drives bone resorption to maintain serum calcium. For mood: vitamin D receptors are expressed in brain regions involved in serotonin synthesis and dopamine regulation. Low vitamin D is associated with lower serotonin production in preclinical studies. The 2023 Menopause review (Grigolon, PMID 36576445) does not establish causality for mood, but the mechanistic pathway is biologically plausible and supported by the association data. For immune function: vitamin D modulates both innate and adaptive immunity. Low vitamin D is associated with increased susceptibility to respiratory infections and with dysregulated inflammatory cytokine responses — both of which become more clinically prominent in the perimenopausal years as estrogen's immunomodulatory effects diminish.

The most important vitamin D3 decision is not which brand you buy — it is getting your baseline 25-hydroxyvitamin D level tested before choosing a dose. A woman with a level of 15 ng/mL needs a very different protocol from one at 28 ng/mL. Many clinicians use 1500–2000 IU/day as a maintenance dose for women with levels in the 20–30 ng/mL range; women with levels below 20 ng/mL often need a supervised loading protocol. Without the test, you are supplementing blind. Dose translation: the strongest bone-outcome data in postmenopausal women comes from RCTs using 1000 IU/day (Macdonald 2013, showing attenuation at 1000 IU but not 400 IU) and 2000 IU/day (used in many subsequent trials). The 400 IU dose available in many multivitamins is below the threshold shown to protect hip bone density in the key RCT. This is the principal reason we did not rank any 400 IU product. The K2 question: vitamin K2 (as MK-7 or MK-4) activates osteocalcin, the bone matrix protein that binds calcium. There is mechanistic rationale for combining D3 and K2 for perimenopause bone protection, and the Thorne D3+K2 product addresses this. However, the clinical evidence base for the combination is less robust than for D3 alone, and whether K2 addition provides incremental benefit over D3 alone at the population level remains an open question. It is not a reason to avoid the combination; it is a reason not to pay a 10x premium over D3 alone unless you have a specific reason to prioritize it. Food-first note: fatty fish, egg yolks, and fortified dairy contribute dietary vitamin D3, but reaching 1000–2000 IU/day through food alone is impractical for most women. Supplementation is the practical solution. Take vitamin D3 with the fattiest meal of the day — absorption is significantly higher with food fat present.